In this trial, patients with PIK3CA-mutated BC received alpelisib plus fulvestrant or fulvestrant alone as a second-line treatment after progression on AI, with a significant improvement of the PFS in the combination group (11 months versus 5.7 months) [160]. This evidence concerns the gene PIK3CA and breast cancer.